The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Open accessAbstract
The sequencing of AML genomes of eight patients before and after relapse reveals two major patterns of clonal evolution, with chemotherapy appearing to have a role in both patterns. Many patients with acute myeloid leukaemia (AML) achieve remission, but it is often short-lived and the returned disease is usually refractory to therapy. Genome sequencing of eight patients with AML before and after relapse reveals two major patterns of tumour cell evolution. The founding clone survives chemotherapy in all patients, and, in one clonal pattern, it acquires new mutations and expands at relapse. In the other, a subclone surviving from the original tumour expands and then acquires new mutations. Comparisons of relapse-specific and primary tumour mutations point to an increase in transversions, implying DNA damage caused by cytotoxic chemotherapy. This work demonstrates that the AML genome in an individual patient presents a moving target, and highlights the importance of striving to eradicate both the founding clone and all of its subclones. Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level1,2 . To determine the mutational spectrum associated with relapse, we sequenced the primary tumour and relapse genomes from eight AML patients, and validated hundreds of somatic mutations using deep sequencing; this allowed us to define clonality and clonal evolution patterns precisely at relapse. In addition to discovering novel, recurrently mutated genes (for example, WAC, SMC3, DIS3, DDX41 and DAXX) in AML, we also found two major clonal evolution patterns during AML relapse: (1) the founding clone in the primary tumour gained mutations and evolved into the relapse clone, or (2) a subclone of the founding clone survived initial therapy, gained additional mutations and expanded at relapse. In all cases, chemotherapy failed to eradicate the founding clone. The comparison of relapse-specific versus primary tumour mutations in all eight cases revealed an increase in transversions, probably due to DNA damage caused by cytotoxic chemotherapy. These data demonstrate that AML relapse is associated with the addition of new mutations and clonal evolution, which is shaped, in part, by the chemotherapy that the patients receive to establish and maintain remissions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”
From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Ding et al., 2012
In the citing paper
“For example, the clonal architecture of de novo AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy 9.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationTumour evolution inferred by single-cell sequencing
Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook, K., Stepansky, A., Levy, D., Esposito, D., et al. (2011) · Nature · doi:10.1038/nature09807 · Cited by 2,598
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Recurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Self-citationWard, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Self-citationCytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
Puente, X. S., Pinyol, M., Quesada, V., Conde, L., Ordóñez, G. R., Villamor, N., Escaramís, G., Jares, P., Beà, S., González, M., et al. (2011) · Nature · doi:10.1038/nature10113 · Cited by 1,529
BreakDancer: an algorithm for high-resolution mapping of genomic structural variation
Chen, K., Wallis, J. W., McLellan, M. D., Larson, D. E., Kalicki, J. M., Pohl, C. S., McGrath, S. D., Wendl, M. C., Zhang, Q., Locke, D. P., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1363 · Cited by 1,489
Cited by
Sorted by citations
Items 301–400 of 999
Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia
Parkin, B. L., Ouillette, P. D., Li, Y., Keller, J. A., Lam, C., Roulston, D., Li, C., Shedden, K., & Malek, S. N. (2012) · Blood · doi:10.1182/blood-2012-04-427039 · Cited by 123
Hoelper, D., Huang, H., Jain, A. Y., Patel, D. J., & Lewis, P. W. (2017) · Nature Communications · doi:10.1038/s41467-017-01206-y · Cited by 127
Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment
Eguchi, T., Sogawa, C. A., Okusha, Y., Uchibe, K., Iinuma, R., Ono, K., Nakano, K., Murakami, J., Itoh, M., Arai, K., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191109 · Cited by 123
Warnat-Herresthal, S., Perrakis, K., Taschler, B., Becker, M., Baßler, K., Beyer, M., Günther, P., Schulte-Schrepping, J., Seep, L., Klee, K., et al. (2020) · iScience · doi:10.1016/j.isci.2019.100780 · Cited by 117
Pollyea, D. A., Gutman, J. A., Gore, L., Smith, C. A., & Jordan, C. T. (2014) · Haematologica · doi:10.3324/haematol.2013.085209 · Cited by 122
Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia
Percival, M. M., Lai, C., Estey, E. H., & Hourigan, C. S. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.01.003 · Cited by 122
Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity
Lamble, A. J., & Lind, E. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00213 · Cited by 119
Single cell analysis of cancer genomes
Loo, P. V., & Voet, T. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.12.004 · Cited by 118
FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia
Leung, A. Y. H., Man, C., & Kwong, Y. (2012) · Leukemia · doi:10.1038/leu.2012.195 · Cited by 117
Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take
Altea‐Manzano, P., Cuadros, A. M., Broadfield, L. A., & Fendt, S. (2020) · EMBO Reports · doi:10.15252/embr.202050635 · Cited by 123
The impact of intra-clonal heterogeneity on the treatment of multiple myeloma
Brioli, A., Melchor, L., Cavo, M., & Morgan, G. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.12805 · Cited by 116
Allison, K. H., & Sledge, G. W. (2014) · PubMed · Cited by 111
Tumor Heterogeneity Confounds and Illuminates: Assessing the implications
Kleppe, M., & Levine, R. L. (2014) · Nature Medicine · doi:10.1038/nm.3522 · Cited by 113
Stieber, D., Golebiewska, A., Evers, L., Lenkiewicz, E., Brons, N. H. C., Nicot, N., Oudin, A., Bougnaud, S., Hertel, F., Bjerkvig, R., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1196-4 · Cited by 112
Mutational History of a Human Cell Lineage from Somatic to Induced Pluripotent Stem Cells
Rouhani, F. J., Nik‐Zainal, S., Wüster, A., Li, Y., Conte, N., Koike-Yusa, H., Kumasaka, N., Vallier, L., Yusa, K., & Bradley, A. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005932 · Cited by 113
Blackburn, J. S., Liu, S., Wilder, J. L., Dobrinski, K. P., Lobbardi, R., Moore, F. E., Martinez, S. A., Chen, E. Y., Lee, C., & Langenau, D. M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.032 · Cited by 111
The Impact of Next-Generation Sequencing on Cancer Genomics: From Discovery to ClinicPreprint
Mardis, E. R. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036269 · Cited by 118
Next-generation sequencing: recent applications to the analysis of colorectal cancer
Vecchio, F. D., Mastroiaco, V., Marco, A. D., Compagnoni, C., Capece, D., Zazzeroni, F., Capalbo, C., Alesse, E., & Tessitore, A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1353-y · Cited by 110
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
Herrmann, H., Sadovnik, I., Eisenwort, G., Rülicke, T., Blatt, K., Herndlhofer, S., Willmann, M., Stefanzl, G., Baumgartner, S., Greiner, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001742 · Cited by 112
Intratumoral heterogeneity and drug resistance in cancer
Fu, Y.-C., Liang, S.-B., Luo, M., & Wang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03734-w · Cited by 129
Genome evolution during progression to breast cancerPreprint
Newburger, D. E., Kashef-Haghighi, D., Weng, Z., Salari, R., Sweeney, R. T., Brunner, A. L., Zhu, S., Guo, X., Varma, S., Troxell, M. L., et al. (2013) · Genome Research · doi:10.1101/gr.151670.112 · Cited by 108
Wong, T. N., Miller, C. A., Klco, J. M., Petti, A. A., Demeter, R., Helton, N., Li, T., Fulton, R. S., Heath, S. E., Mardis, E. R., et al. (2015) · Blood · doi:10.1182/blood-2015-10-677021 · Cited by 108
Inferring Clonal Composition from Multiple Sections of a Breast Cancer
Zare, H., Wang, J., Hu, A. K., Weber, K., Smith, J., Nickerson, D. A., Song, C.-Z., Witten, D., Blau, C. A., & Noble, W. S. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003703 · Cited by 103
Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma
Kurth, I., Hein, L., Mäbert, K., Peitzsch, C., Koi, L., Cojoc, M., Kunz‐Schughart, L. A., Baumann, M. A., & Dubrovska, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5417 · Cited by 107
Morris, Q., Liu, P., Woloszynska‐Read, A., Zhang, J., Luo, W. F., Qin, M., Bshara, W., Conroy, J. M., Sabatini, L. M., Vedell, P. T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313580111 · Cited by 107
Hajirasouliha, I., Mahmoody, A., & Raphael, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu284 · Cited by 106
Intratumor heterogeneity alters most effective drugs in designed combinations
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323934111 · Cited by 105
Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
Uy, G. L., Duncavage, E. J., Chang, G. S., Jacoby, M. A., Miller, C. A., Shao, J., Heath, S. C., Elliott, K., Reineck, T., Fulton, R. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.282 · Cited by 108
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?
Loke, J. C. T., Buka, R. J., & Craddock, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.659595 · Cited by 119
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 108
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
Yilmaz, M. E., Wang, F., Loghavi, S., Bueso-Ramos, C., Gumbs, C. E., Little, L., Song, X., Zhang, J., Kadia, T. M., Borthakur, G. M., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0170-3 · Cited by 108
Cohesin subunit RAD21: From biology to disease
Cheng, H., Zhang, N., & Pati, D. (2020) · Gene · doi:10.1016/j.gene.2020.144966 · Cited by 103
Xu, J., Wang, Y., Dai, Y., Zhang, W., Zhang, W.-N., Xiong, S.-M., Gu, Z., Wang, K., Zeng, R., Zhu, C. H., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400150111 · Cited by 104
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
Vick, B., Rothenberg, M., Sandhöfer, N., Carlet, M., Finkenzeller, C., Krupka, C., Grunert, M., Trumpp, A., Corbacioglu, S., Ebinger, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120925 · Cited by 105
An evolutionary perspective on chronic myelomonocytic leukemia
Itzykson, R., & Solary, É. (2013) · Leukemia · doi:10.1038/leu.2013.100 · Cited by 108
The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process
Wu, C., Wang, H., Ling, S., & Lu, X. (2016) · Annual Review of Genetics · doi:10.1146/annurev-genet-112414-054842 · Cited by 106
Acute Myeloid Leukemia and the Bone Marrow Niche—Take a Closer Look
Behrmann, L., Wellbrock, J., & Fiedler, W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00444 · Cited by 108
Wang, Z., Cai, J., Cheng, J., Yang, W., Zhu, Y., Li, H., Lu, T., Chen, Y., & Lü, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01851 · Cited by 104
Addressing Genetic Tumor Heterogeneity through Computationally Predictive Combination Therapy
Zhao, B., Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0465 · Cited by 98
Raynaud, F., Mina, M., Tavernari, D., & Ciriello, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007669 · Cited by 106
Next-Generation Sequencing in Acute Lymphoblastic Leukemia
Coccaro, N., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122929 · Cited by 99
Chitalia, R., Rowland, J., McDonald, E. S., Pantalone, L., Cohen, E. A., Gastounioti, A., Feldman, M. D., Schnall, M. D., Conant, E. F., & Despina Kontos, B. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4067 · Cited by 102
Understanding resistance to combination chemotherapy
Pritchard, J. R., Lauffenburger, D. A., & Hemann, M. T. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.10.003 · Cited by 100
Han, L., Qiu, P., Zeng, Z., Jorgensen, J. L., Mak, D. H. F., Burks, J. K., Schober, W. D., McQueen, T. J., Cortes, J. E., Tanner, S. D., et al. (2015) · Cytometry Part A · doi:10.1002/cyto.a.22628 · Cited by 100
Do mutator mutations fuel tumorigenesis?
Fox, E. J., Prindle, M. J., & Loeb, L. A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9426-8 · Cited by 109
FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations
Käyser, S., & Levis, M. J. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.800198 · Cited by 102
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Cesne, A. L., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., Jonge, M. J. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 105
Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
Chen, K., Meric‐Bernstam, F., Zhao, H., Zhang, Q. C., Ezzeddine, N., Tang, L.-Y., Qi, Y., Mao, Y., Chen, T., Chong, Z., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231100 · Cited by 97
Chisholm, R. H., Lorenzi, T., & Clairambault, J. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.06.009 · Cited by 99
Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
Gebru, M. T., & Wang, H. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00992-1 · Cited by 98
Stiehl, T., Baran, N., Ho, A. D., & Marciniak-Czochra, A. K. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2508 · Cited by 97
Debarri, H., Lebon, D., Roumier, C., Cheok, M. H.-C., Marceau‐Renaut, A., Nibourel, O., Geffroy, S., Hélevaut, N., Rousselot, P. H., Gruson, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5645 · Cited by 108
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
Cho, B., Kim, H., & Konopleva, M. Y. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.244 · Cited by 97
Utility of pooled sequencing for association mapping in nonmodel organisms
Micheletti, S. J., & Narum, S. R. (2018) · Molecular Ecology Resources · doi:10.1111/1755-0998.12784 · Cited by 98
Single-Cell Sequencing Technologies: Current and Future
Liang, J., Cai, W., & Sun, Z. S. (2014) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2014.09.005 · Cited by 101
Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia
Naldini, M. M., Casirati, G., Barcella, M., Rancoita, P. M. V., Cosentino, A., Caserta, C., Pavesi, F., Zonari, E., Desantis, G., Gilioli, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36969-0 · Cited by 97
Liu, B., Morrison, C. D., Johnson, C. S., Trump, D. L., Qin, M., Conroy, J., Wang, J., & Liu, S. (2013) · Oncotarget · doi:10.18632/oncotarget.1537 · Cited by 96
BCL9L Dysfunction Impairs Caspase-2 Expression Permitting Aneuploidy Tolerance in Colorectal Cancer
López‐García, C., Sansregret, L., Domingo, E., McGranahan, N., Hobor, S., Birkbak, N. J., Horswell, S. D., Gronroos, E. C., Favero, F., Rowan, A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.001 · Cited by 94
Cellular cooperation: insights from microbes
Celiker, H., & Gore, J. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.08.010 · Cited by 94
Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
Findlay, J. M., Castro-Giner, F., Makino, S., Rayner, E., Kartsonaki, C., Cross, W. C. H., Kovac, M. B., Ulahannan, D., Palles, C., Gillies, R. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11111 · Cited by 97
Mechanisms of genome instability induced by RNA-processing defects
Chan, Y. A., Hieter, P., & Stirling, P. C. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.03.005 · Cited by 96
The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome
Larsson, C. A., Cote, G. J., & Quintás‐Cardama, A. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0695 · Cited by 97
Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M. W., Vyas, P., Goldstone, A. H., Milligan, D. W., Clark, R. E., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.148825 · Cited by 94
Tumor heterogeneity makes AML a “moving target” for detection of residual disease
Zeijlemaker, W., Gratama, J. W., & Schuurhuis, G. J. (2013) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21134 · Cited by 127
TPL2 kinase regulates the inflammatory milieu of the myeloma niche
Hope, C. L., Ollar, S. J., Héninger, E., Hebron, E., Jensen, J. L., Kim, J., Maroulakou, I. G., Miyamoto, S., Leith, C. P., Yang, D. T., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554071 · Cited by 95
Wang, H., Li, W., Guo, R., Sun, J., Cui, J., Wang, G., Hoffman, A. R., & Hu, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28922 · Cited by 94
Heterogeneity and Tumor History
Shibata, D. K. (2012) · Science · doi:10.1126/science.1222361 · Cited by 93
A Proteomics and Transcriptomics Approach to Identify Leukemic Stem Cell (LSC) Markers
Bonardi, F., Fusetti, F., Deelen, P., van Gosliga, D., Vellenga, E., & Schuringa, J. J. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.021931 · Cited by 96
Bailey, M. L., O’Neil, N. J., van Pel, D. M., Solomon, D. A., Waldman, T. A., & Hieter, P. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0749 · Cited by 100
Choi, E.-R., Lee, H. Y., Jeong, J. Y., Choi, Y., Kim, J., Bae, J., Lee, K. S., & Shim, Y. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11693 · Cited by 91
Chen, X., & Wood, B. L. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.09.006 · Cited by 94
METTL3 mediates chemoresistance by enhancing AML homing and engraftment via ITGA4
Li, M., Ye, J., Xia, Y., Li, M., Li, G., Hu, X., Su, X., Wang, D., Zhao, X., Lu, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01696-w · Cited by 92
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
Neuendorff, N. R., Burmeister, T., Dörken, B., & Westermann, J. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2721-z · Cited by 98
Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer EvolutionPreprint
Venkatesan, S., Swanton, C., Taylor, B. S., & Costello, J. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026617 · Cited by 94
Stetson, L. C., Balasubramanian, D., Ribeiro, S. P., Stefan, T., Gupta, K., Xu, X., Fourati, S., Roe, A. J., Jackson, Z., Schauner, R., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01338-7 · Cited by 85
Lee, J., Yoon, J.-K., Kim, B., Kim, S., Kim, M. A., Lim, H., Bang, D., & Song, Y. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1077-4 · Cited by 90
Jiang, Y., Redmond, D., Nie, K., Eng, K. W., Clozel, T., Martin, P., Tan, L. H. C., Melnick, A. M., Tam, W., & Elemento, O. (2014) · Genome biology · doi:10.1186/s13059-014-0432-0 · Cited by 99
Identification of Gene Mutations and Fusion Genes in Patients with Sézary Syndrome
Prasad, A., Rabionet, R., Espinet, B., Zapata, L., Puiggros, A., Melero, C., Puig, A., Sarria, Y., Ossowski, S., García-Muret, M. P., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.024 · Cited by 92
The emerging roles of the DDX41 protein in immunity and diseases
Jiang, Y., Zhu, Y., Liu, Z., & Ouyang, S. (2016) · Protein & Cell · doi:10.1007/s13238-016-0303-4 · Cited by 93
Krook, M. A., Bonneville, R., Chen, H., Reeser, J. W., Wing, M. R., Patacsil, D., Smith, A. M., Dao, T., Samorodnitsky, E., Paruchuri, A., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a004002 · Cited by 89
Precision therapy for lymphoma—current state and future directions
Intlekofer, A. M., & Younes, A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.137 · Cited by 91
Understanding of leukemic stem cells and their clinical implications
Wang, X., Huang, S., & Chen, J. (2017) · Molecular Cancer · doi:10.1186/s12943-016-0574-7 · Cited by 92
Genetic and Non-Genetic Mechanisms Underlying Cancer Evolution
Shlyakhtina, Y., Moran, K. L., & Portal, M. M. (2021) · Cancers · doi:10.3390/cancers13061380 · Cited by 91
SnapShot: Acute Myeloid Leukemia
Zeisig, B. B., Kulasekararaj, A. G., Mufti, G. J., & So, C. W. E. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.10.017 · Cited by 89
Stiehl, T., Baran, N., Ho, A. D., & Marciniak-Czochra, A. (2014) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.0079 · Cited by 86
Intra‐tumour heterogeneity – going beyond genetics
Caiado, F., Silva‐Santos, B., & Norell, H. (2016) · FEBS Journal · doi:10.1111/febs.13705 · Cited by 87
Parallel evolution of tumour subclones mimics diversity between tumours
Martinez, P., Birkbak, N. J., Gerlinger, M., McGranahan, N., Burrell, R. A., Rowan, A., Joshi, T., Fisher, R. A., Larkin, J., Szállási, Z., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4214 · Cited by 88
Leukaemia 'firsts' in cancer research and treatment
Greaves, M. F. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.3 · Cited by 90
Greif, P. A., Hartmann, L., Vosberg, S., Stief, S. M., Mattes, R., Hellmann, I., Metzeler, K. H., Herold, T., Bamopoulos, S. A., Kerbs, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2344 · Cited by 88
Childhood acute myeloid leukaemia
Rubnitz, J. E., & Inaba, H. (2012) · British Journal of Haematology · doi:10.1111/bjh.12040 · Cited by 89
Tang, Q., Moore, J. C., Ignatius, M. S., Tenente, I. M., Hayes, M. N., Garcia, E. G., Yordán, N. T., Bourque, C., He, S., Blackburn, J. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms10358 · Cited by 91
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia
Ding, L., Sun, Q., Tan, K. T., Chien, W., Mayakonda, A., Yeoh, A. E. J., Kawamata, N., Nagata, Y., Xiao, J., Loh, X.-Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1303 · Cited by 87
Garcia‐Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M. L., Khaled, S. K., Patnaik, M. M., Odenike, O. M., Sayar, H., Tummala, M. K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 88
Translating insights into tumor evolution to clinical practice: promises and challenges
Fittall, M. W., & Loo, P. V. (2019) · Genome Medicine · doi:10.1186/s13073-019-0632-z · Cited by 91
Campana, D., & Leung, W. H. (2013) · British Journal of Haematology · doi:10.1111/bjh.12358 · Cited by 90
An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells
Peitzsch, C., Cojoc, M., Hein, L., Kurth, I., Mäbert, K., Trautmann, F., Klink, B., Schröck, E., Wirth, M. P., Krause, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2116 · Cited by 87
Cancer classification in the genomic era: five contemporary problems
Song, Q., Merajver, S. D., & Li, J. Z. (2015) · Human Genomics · doi:10.1186/s40246-015-0049-8 · Cited by 92
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia
Brown, F. C., Still, E., Koche, R. P., Yim, C. Y., Takao, S., Cifani, P., Reed, C., Gunasekera, S., Ficarro, S. B., Romanienko, P. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1271 · Cited by 85
Metadata
- Authors
- Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., McMichael, J. F., Wallis, J. W., Lu, C., Shen, D., Harris, C. C., Dooling, D. J., Fulton, R. S., Fulton, L. L., Chen, K., Schmidt, H., Kalicki-Veizer, J., Magrini, V. J., Cook, L., McGrath, S. D., Vickery, T. L., Wendl, M. C., Heath, S., Watson, M. A., Link, D. C., Tomasson, M. H., Shannon, W. D., Payton, J. E., Kulkarni, S., Westervelt, P., Walter, M. J., Graubert, T. A., Mardis, E. R., Wilson, R. K., & DiPersio, J. F.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Ley, Timothy J.
- ORCID
- Ding, Li
- Ley, Timothy J.
- Larson, David E.
- Miller, Christopher A.
- Koboldt, Daniel C.
- Welch, John S.
- Ritchey, Julie K.
- McLellan, Michael D.
- McMichael, Joshua F.
- Lu, Charles
- Shen, Dong
- Fulton, Robert S.
- Fulton, Lucinda L.
- Chen, Ken
- Magrini, Vincent J.
- McGrath, Sean D.
- Vickery, Tammi L.
- Wendl, Michael C.
- Heath, Sharon
- Watson, Mark A.
- Link, Daniel C.
- Tomasson, Michael H.
- Payton, Jacqueline E.
- Kulkarni, Shashikant
- Walter, Matthew J.
- Graubert, Timothy A.
- Mardis, Elaine R.
- Wilson, Richard K.
- DiPersio, John F.
- Venue
- Nature
- Published
- 2012-01
- Volume
- 481
- Issue
- 7382
- Pages
- 506-510
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3267864
- OpenAlex
- W2093144236
- Cited by
- 1,993
- References
- 30
- Citations by year
- 2026: 55 · 2025: 50 · 2024: 61 · 2023: 74 · 2022: 116 · 2021: 138 · 2020: 134 · 2019: 151 · 2018: 155 · 2017: 160 · 2016: 197 · 2015: 192 · 2014: 210 · 2013: 182 · 2012: 118
- FWCI
- 149.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Foundation for Barnes-Jewish Hospital (00335-0505-02)
- National Human Genome Research Institute (U54HG003079, HG003079, NHGRI U54 HG003079)
- National Cancer Institute (PO1CA101937, CA101937, P01CA101937)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, relapse, clonal evolution, somatic mutations, subclones, chemotherapy-induced DNA damage, transversions, recurrently mutated genes, WAC, SMC3, DIS3, DDX41, DAXX, clonality
- MeSH terms
- Antineoplastic Agents, Clone Cells, DNA Damage, DNA Mutational Analysis, Humans, Recurrence, Reproducibility of Results, Leukemia, Myeloid, Acute, Genome, Human, Mutagenesis, Genes, Neoplasm, High-Throughput Nucleotide Sequencing, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
